CoChat

Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY

Open access
TODAY Study Group · 2013 · Diabetes Care

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that combination therapy with metformin plus rosiglitazone provided superior durability of glycemic control compared with metformin alone, with significantly lower treatment failure rates (38.6 vs. 51.7%), and metformin plus lifestyle was intermediate. Herein we describe the temporal changes in measures of β-cell function and insulin sensitivity over a 4-year period among the three treatments. RESEARCH DESIGN AND METHODS: TODAY participants (699) were tested periodically with an oral glucose tolerance test to determine insulin sensitivity (1/fasting insulin [1/IF]), insulinogenic index (△I30/△G30) or C-peptide index (△C30/△G30), and β-cell function relative to insulin sensitivity (oral disposition index [oDI]). RESULTS: During the first 6 months, metformin plus rosiglitazone exhibited a significantly greater improvement in insulin sensitivity and oDI versus metformin alone and versus metformin plus lifestyle; these improvements were sustained over 48 months of TODAY. Irrespective of treatment, those who failed to maintain glycemic control had significantly lower β-cell function (∼50%), higher fasting glucose concentration, and higher HbA1c at randomization compared with those who did not fail. CONCLUSIONS: The beneficial change in insulin sensitivity and the resultant lower burden on β-cell function achieved in the first 6 months with metformin plus rosiglitazone appear to be responsible for its superior glycemic durability over metformin alone and metformin plus lifestyle. However, initial β-cell reserve and HbA1c at randomization are independent predictors of glycemic durability. Therefore, efforts to preserve β-cell function before significant loss occurs and to reduce HbA1c may be beneficial in the treatment of youth with type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc12-2393

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Baseline adjusted geometric mean ± SE asymmetric limits (obtained as exp[mean ± SE of log values]) of OGTT-derived measures of insulin sensitivity (1/IF) (A), insulinogenic index (△I30/△G30) (B), and oDI ([1/IF] × [△C30/△G30]) (C) in the three treatment groups over 48 months of follow-up in TODAY, analyzed using log-transformed values. The P value refers to the overall effect of treatment group assignment in the longitudinal models for the various parameters under question within the groups.
Figure 1 Baseline adjusted geometric mean ± SE asymmetric limits (obtained as exp[mean ± SE of log values]) of OGTT-derived measures of insulin sensitivity (1/IF) (A), insulinogenic index (△I30/△G30) (B), and oDI ([1/IF] × [△C30/△G30]) (C) in the three treatment groups over 48 months of follow-up in TODAY, analyzed using log-transformed values. The P value refers to the overall effect of treatment group assignment in the longitudinal models for the various parameters under question within the groups.CC BY-NC-ND · PubMed Central
Figure 2 Baseline adjusted geometric mean ± SE asymmetric limits (obtained as exp[mean ± SE of log values]) of OGTT-derived measures by treatment failure with the three treatment groups combined, analyzed using log-transformed values. A: Insulin sensitivity (1/IF). B: Insulinogenic index (△I30/△G30). C: oDI ([1/IF] × [△C30/△G30]). The P value refers to the overall effect of failed vs. not failed group assignment in the longitudinal models for the various parameters under question within the two groups.
Figure 2 Baseline adjusted geometric mean ± SE asymmetric limits (obtained as exp[mean ± SE of log values]) of OGTT-derived measures by treatment failure with the three treatment groups combined, analyzed using log-transformed values. A: Insulin sensitivity (1/IF). B: Insulinogenic index (△I30/△G30). C: oDI ([1/IF] × [△C30/△G30]). The P value refers to the overall effect of failed vs. not failed group assignment in the longitudinal models for the various parameters under question within the two groups.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 288

Metadata

Authors
TODAY Study Group
Corresponding author
TODAY Study Group
Venue
Diabetes Care
Published
2013-05-15
Volume
36
Issue
6
Pages
1749-1757
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W59232989
Cited by
288
References
25
Citations by year
2026: 10 · 2025: 26 · 2024: 30 · 2023: 25 · 2022: 37 · 2021: 28 · 2020: 27 · 2019: 16 · 2018: 23 · 2017: 12 · 2016: 12 · 2015: 16 · 2014: 18 · 2013: 8
FWCI
14.08
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (UL1TR000130, UL1TR000005, UL1TR000448, UL1TR000439)
  • National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061239, U01DK061212, U01DK061254, U01DK061242, U01DK061230)
  • National Center for Research Resources (M01RR000125, UL1RR024989, UL1RR025758, M01RR001066, UL1RR024153, UL1RR024134, M01RR000043, M01‐RR00043‐45, M01RR014467, M01RR000069, UL1RR024992, UL1RR024139, M01RR000084, M01RR000036, UL1RR025780)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
metformin, rosiglitazone, insulin sensitivity, beta-cell function, oral disposition index, insulinogenic index, treatment failure, beta-cell reserve
MeSH terms
Adolescent, Child, Diabetes Mellitus, Type 2, Drug Combinations, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Life Style, Male, Metformin, Thiazoles, Insulin-Secreting Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY. https://app.cochat.ai/papers/10.2337/dc12-2393
The paper
TODAY Study Group. (2013). Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY. Diabetes Care. https://doi.org/10.2337/dc12-2393

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.